Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
Select Content Type
Clinical Guidelines
Authored By
Brown, Patrick , Inaba, Hiroto , Annesley, Colleen , Beck, Jill , Colace, Susan , Dallas, Mari , DeSantes, Kenneth , Kelly, Kara , Kitko, Carrie , Lacayo, Norman , Larrier, Nicole , Maese, Luke , Mahadeo, Kris , Nanda, Ronica , Nardi, Valentina , Rodriguez, Vilmarie , Rossoff, Jenna , Schuettpelz, Laura , Silverman, Lewis , Sun, Jessica , Sun, Weili , Teachey, David , Wong, Victor , Yanik, Gregory , Johnson-Chilla, Alyse , Ogba, Ndiya
Interests
Oncology
Hematology
Pediatric Medicine
Book Detail
Publisher
Harborside Press
volume
18
ISSN
1540-1413 ; Electronic
No. of pages
32
Actions
Download in App
Event Data
{"article_title":"Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.","author":"Brown, Patrick , Inaba, Hiroto , Annesley, Colleen , Beck, Jill , Colace, Susan , Dallas, Mari , DeSantes, Kenneth , Kelly, Kara , Kitko, Carrie , Lacayo, Norman , Larrier, Nicole , Maese, Luke , Mahadeo, Kris , Nanda, Ronica , Nardi, Valentina , Rodriguez, Vilmarie , Rossoff, Jenna , Schuettpelz, Laura , Silverman, Lewis , Sun, Jessica , Sun, Weili , Teachey, David , Wong, Victor , Yanik, Gregory , Johnson-Chilla, Alyse , Ogba, Ndiya","journal_title":"Journal of the National Comprehensive Cancer Network : JNCCN","issn":"1540-1413 ; Electronic","isbn":"","publication_date":"20200101","volume":"18","issue":"1","first_page":"81","page_count":"32","accession_number":"31910389","doi":"10.6004\/jnccn.2020.0001","publisher":"Harborside Press","doctype":"Journal Article; Practice Guideline","subjects":"Pediatrics","interest_area":["Oncology"," Hematology"," Pediatric Medicine"],"abstract":"Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. Advancements in technology that enhance our understanding of the biology of the disease, risk-adapted therapy, and enhanced supportive care have contributed to improved survival rates. However, additional clinical management is needed to improve outcomes for patients classified as high risk at presentation (eg, T-ALL, infant ALL) and who experience relapse. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for pediatric ALL provide recommendations on the workup, diagnostic evaluation, and treatment of the disease, including guidance on supportive care, hematopoietic stem cell transplantation, and pharmacogenomics. This portion of the NCCN Guidelines focuses on the frontline and relapsed\/refractory management of pediatric ALL.","url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&db=mdl&AN=31910389&authtype=shib&custid=ns346513"}
Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. Advancements in technology that enhance our understanding of the biology of the disease, risk-adapted therapy, and enhanced supportive care have contributed to improved survival rates. However, additional clinical management is needed to improve outcomes for patients classified as high risk at presentation (eg, T-ALL, infant ALL) and who experience relapse. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for pediatric ALL provide recommendations on the workup, diagnostic evaluation, and treatment of the disease, including guidance on supportive care, hematopoietic stem cell transplantation, and pharmacogenomics. This portion of the NCCN Guidelines focuses on the frontline and relapsed/refractory management of pediatric ALL.
